Significance of TP53 mutation in bladder cancer disease progression and drug selection
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Significance of TP53 mutation in bladder cancer disease progression and drug selection
Authors
Keywords
-
Journal
PeerJ
Volume 7, Issue -, Pages e8261
Publisher
PeerJ
Online
2019-12-16
DOI
10.7717/peerj.8261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
- (2018) Toshinori Ozaki et al. BMC CANCER
- Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis
- (2018) Ding Jian et al. Journal of Cancer Research and Therapeutics
- Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
- (2018) Sony Pandey et al. Oncotarget
- Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2018) John P Vanden Heuvel et al. eLife
- Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?
- (2017) Cyrill A. Rentsch et al. EUROPEAN UROLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63
- (2016) Toshinori Ozaki et al. Oncotarget
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
- (2015) Michael Paul Kim et al. Frontiers in Oncology
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
- (2014) Y. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden
- (2014) J. -B. Cazier et al. Nature Communications
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation
- (2012) Davis J. McCarthy et al. NUCLEIC ACIDS RESEARCH
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
- (2011) Yaoting Gui et al. NATURE GENETICS
- Prognostic Value of p53 and Ki-67 Expression in Intermediate-risk Patients With Nonmuscle-invasive Bladder Cancer Receiving Adjuvant Intravesical Mitomycin C Therapy
- (2010) Ho Kyung Seo et al. UROLOGY
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
- EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis
- (2009) R. A. Mason et al. CARCINOGENESIS
- Blinded by the Light: The Growing Complexity of p53
- (2009) Karen H. Vousden et al. CELL
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
- (2009) J. P. Morton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Altered redox status accompanies progression to metastatic human bladder cancer
- (2008) N HEMPEL et al. FREE RADICAL BIOLOGY AND MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started